Paper35683032
Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S and 4 others. Int J Mol Sci, 2022. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α. Papers, record 35683032. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35683032
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bile Duct Neoplasms | Major topic |
| Cholangiocarcinoma | Major topic |
| Bile Ducts, Intrahepatic | |
| Casein Kinase II | |
| Caspase 9 | |
| Cell Line, Tumor | |
| Eukaryotic Initiation Factor-2 | |
| Humans | |
| Naphthyridines | |
| Phenazines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022R1A2C4001769 | National Research Foundation of Korea | PubMed |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32606456 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32606456 | PubMed |
| 2 | 25081716 | High expression of HIF-1α, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis. | Asian Pac J Cancer Prev | 2014 | https://conductscience.org/library/papers/25081716 | PubMed |
| 3 | 30316146 | Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. | Transl Oncol | 2019 | https://conductscience.org/library/papers/30316146 | PubMed |
| 4 | 27479180 | Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia. | Leukemia | 2017 | https://conductscience.org/library/papers/27479180 | PubMed |
| 5 | 24609900 | Translational regulator eIF2α in tumor. | Tumour Biol | 2014 | https://conductscience.org/library/papers/24609900 | PubMed |
| 6 | 26151455 | The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. | Br J Cancer | 2015 | https://conductscience.org/library/papers/26151455 | PubMed |
| 7 | 21174434 | Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. | J Med Chem | 2011 | https://conductscience.org/library/papers/21174434 | PubMed |
| 8 | 31641101 | The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. | Oncogenesis | 2019 | https://conductscience.org/library/papers/31641101 | PubMed |
| 9 | 26508039 | Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. | Hepatol Res | 2016 | https://conductscience.org/library/papers/26508039 | PubMed |
| 10 | 21940327 | Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. | Hepatogastroenterology | 2011 | https://conductscience.org/library/papers/21940327 | PubMed |
| 11 | 16489027 | Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. | Cancer Res | 2006 | https://conductscience.org/library/papers/16489027 | PubMed |
| 12 | 23925046 | Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia. | Leukemia | 2014 | https://conductscience.org/library/papers/23925046 | PubMed |
| 13 | 27480717 | Measuring Survival of Adherent Cells with the Colony-Forming Assay. | Cold Spring Harb Protoc | 2016 | https://conductscience.org/library/papers/27480717 | PubMed |
| 14 | 25153725 | Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. | Oncotarget | 2014 | https://conductscience.org/library/papers/25153725 | PubMed |
| 15 | 26911335 | Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. | BMC Nephrol | 2016 | https://conductscience.org/library/papers/26911335 | PubMed |
| 16 | 23828693 | Overexpressions of CK2β and XIAP are associated with poor prognosis of patients with cholangiocarcinoma. | Pathol Oncol Res | 2014 | https://conductscience.org/library/papers/23828693 | PubMed |
| 17 | 17461440 | Multi-disciplinary treatment for cholangiocellular carcinoma. | World J Gastroenterol | 2007 | https://conductscience.org/library/papers/17461440 | PubMed |
| 18 | 34944749 | The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer. | Biomedicines | 2021 | https://conductscience.org/library/papers/34944749 | PubMed |
| 19 | 31789392 | Anti‑survival and pro‑apoptotic effects of meridianin C derivatives on MV4‑11 human acute myeloid leukemia cells. | Int J Oncol | 2020 | https://conductscience.org/library/papers/31789392 | PubMed |
| 20 | 33148274 | Eukaryotic translation initiation factors as promising targets in cancer therapy. | Cell Commun Signal | 2020 | https://conductscience.org/library/papers/33148274 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40280109 | Anticancer effects of salvianolic acid A through multiple signaling pathways (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/40280109 | PubMed |
| 39925432 | Single-cell and spatial transcriptomics reveal pre-metastatic subsets and therapeutic targets in penile carcinoma. | iScience | 2025 | https://conductscience.org/library/papers/39925432 | PubMed |
| 39862423 | Targeting the IKZF1/BCL-2 axis as a novel therapeutic strategy for treating acute T-cell lymphoblastic leukemia. | Cancer Biol Ther | 2025 | https://conductscience.org/library/papers/39862423 | PubMed |
| 39618935 | Targeting Glycolytic Reprogramming in Cholangiocarcinoma: A Novel Approach for Metabolic Therapy. | J Inflamm Res | 2024 | https://conductscience.org/library/papers/39618935 | PubMed |
| 39300073 | The p-MYH9/USP22/HIF-1α axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/39300073 | PubMed |
| 38730642 | Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38730642 | PubMed |
| 37022795 | Long noncoding RNA HIKER regulates erythropoiesis in Monge's disease via CSNK2B. | J Clin Invest | 2023 | https://conductscience.org/library/papers/37022795 | PubMed |
| 35806278 | Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35806278 | PubMed |
Genes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35683032
GET https://conductscience.org/api/papers/v1/35683032/references?page=2